Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: Long-term follow-up of a randomized clinical trial

British Journal of Haematology

Volumn 110, Issue 3, 2000, Pages 577-583

  Finazzi, Guido ^a,b   Ruggeri, Marco ^c   Rodeghiero, Francesco ^c   Barbui, Tiziano ^a,b  

^a Haematology Division   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c SAN BORTOLO HOSPITAL   (Italy)

Author keywords

Busulphan; Chronic myeloproliferative disorders; Essential thrombocythaemia; Hydroxyurea; Secondary leukaemia

Indexed keywords

BUSULFAN; HYDROXYUREA;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECOND CANCER; SOLID TUMOR; SURVIVAL; THROMBOCYTHEMIA; THROMBOSIS; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYUREA; LEUKEMIA; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOSIS;

EID: 0033781129     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2000.02188.x     Document Type: Article

References (21)

1. Proposals for the classification of the myelodysplastic syndromes
2. Treatment of polycythemia vera. A summary of clinical trials conducted by the PVSG
3. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythaemia
4. Hydroxyurea in the treatment of patients with essential thrombocythaemia at high risk of thrombosis: A prospective, randomized trial
5. Interferon-alpha in the treatment of essential thrombocythaemia
6. Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease
7. Essential thrombocythaemia: An interim report from the Polycythemia Vera Study Group
8. Experience of the Polycythemia Vera Study Group with essential thrombocythaemia: A final report on diagnostic criteria, survival and leukemic transition by treatment
9. Treatment of polycythemia vera: The use of hydroxyurea and pipobroman in 242 patients under the age of 65 years
10. Treatment of polycythemia vera: Use of 32P alone or in combination with maintenance therapy using hydroxyurea in 434 patients over the age of 65 years
11. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythaemia and myeloid metaplasia with myelofibrosis
12. Essential thrombocythaemia: Another 'heterogeneous' disease better understood?
13. Leukemic transformation in polycythemia vera
14. No treatment for low risk thrombocythaemia: Results from a prospective study
15. Essential thrombocythaemia terminating in acute leukemia with minimal myeloid differentiation. A brief review of recent literature
16. Treatment of essential thrombocythaemia with anagrelide
17. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythaemia treated with hydroxyurea
18. Treatment of polycythaemia vera and essential thrombocythaemia
19. Primary thrombocythaemia treated with busulphan
20. Acute leukaemia after hydroxyurea therapy in polycythemia vera and allied disorders: Prospective study of efficacy and leukaemogenicity with therapeutic implications